Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Journey Medical (DERM) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to -$2.3 million.

  • Journey Medical's Net Income towards Common Stockholders rose 313.81% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.6 million, marking a year-over-year increase of 5308.68%. This contributed to the annual value of -$14.7 million for FY2024, which is 28079.42% down from last year.
  • Latest data reveals that Journey Medical reported Net Income towards Common Stockholders of -$2.3 million as of Q3 2025, which was up 313.81% from -$3.8 million recorded in Q2 2025.
  • Journey Medical's Net Income towards Common Stockholders' 5-year high stood at $16.8 million during Q3 2023, with a 5-year trough of -$21.8 million in Q4 2021.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$4.1 million (2025), whereas its average is -$5.4 million.
  • In the last 5 years, Journey Medical's Net Income towards Common Stockholders crashed by 3681034.48% in 2021 and then soared by 26655.75% in 2023.
  • Over the past 5 years, Journey Medical's Net Income towards Common Stockholders (Quarter) stood at -$21.8 million in 2021, then surged by 51.07% to -$10.6 million in 2022, then soared by 79.86% to -$2.1 million in 2023, then skyrocketed by 173.82% to $1.6 million in 2024, then plummeted by 246.33% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q3 2025, -$3.8 million for Q2 2025, and -$4.1 million during Q1 2025.